ABL Bio - medicine for A Better Life

- Joint Development of Three Bispecific Antibodies… Acquired Global License outside China

- ABL Bio, a Korean Biotech with Industry’s Top-rated Core Technology in Bispecific Antibody and Antibody Drug Conjugate (ADC)

July 26, 2018 - ABL Bio formed a strategic partnership with a Chinese biotech firm I-Mab Biopharma (“I-Mab”).

With this partnership, ABL Bio will conduct joint research with I-Mab on three Bispecific Antibodies (BsAbs) that combine PD-L1 and an undisclosed material. Including the development costs, licenses in China, Korea, and other countries are expected to be shared under different configurations. In addition, ABL Bio acquired the exclusive global rights to another BsAb in regions excluding Greater China.

BsAb shows superior efficacy to monoclonal antibody and due to its low side effects, it reduces pain and stress for the patient. For this reason, BsAb is expected to be the new leading immuno-oncology therapy.

Sang Hoon Lee, the founder and CEO of ABL Bio, said, “We are able to develop the first-in-class and the best-in-class BsAb through the partnership with I-Mab, and also to speed up the process of the development of innovative immunotherapy.” He added, “With the strong synergy between the two firms, I expect this partnership to be an exemplary case in the global biotech industry.”

CEO Jingwu Zang of I-Mab said, “I am excited to have joined with ABL Bio which has the world’s best technology in BsAb. We will do our best to develop the antibody that will lead the next-generation immuno-oncology therapy.”

ABL Bio currently holds core technologies in BsAb and Antibody Drug Conjugate (ADC), the next-generation antibody therapeutics platforms in the area of targeted anti-cancer therapy, immuno-oncology, and Parkinson’s Disease. For the first time in Korea, it is currently in Phase 1 clinical trial of ‘ABL-001’, the first new candidate for BsAb.